Pharmaceutical compounds

A compound of Formula III 25

• R1 is selected from the group consisting of hydrogen, —OR4, —SR5, C1-C3 alkyl, C2-C3 alkenyl, halo, —CN, S(O)m2, —COR4b′, and —OC(O)—R15;
• m2 is from 0 to 2;
• R2 is selected from the group consisting of C1-C10 alkyl, substituted C1-C10 alkyl,
• C2-C10 alkenyl, substituted C2-C10 alkenyl, C3-C8 cycloalkyl, substituted C3-C8 cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic;
• R4 is hydrogen, C1-C3 alkyl;
• R5 is hydrogen, C1-C3 alkyl;
• R10 is selected from the group consisting of hydrogen, carbonyl, halo, and C1-C3 alkyl;
• R11 is selected from the group consisting of hydrogen and C1-C3 alkyl;
• R12 is independently selected from the group consisting of hydrogen, C1-C10 alkyl, and aryl;
• R13 is independently selected from the group consisting of hydrogen, C1-C10 alkyl, and aryl;
• or
• R12 and R13 together with the nitrogen to which they are attached form a group of the formula II:
• 26
• II′ wherein the II′ group is a group of Formula II which is unsaturated;
• or
• R11 and R12 together with the nitrogen and carbon to which they are bound can join to form a three to six membered ring;
• R14 is selected from the group consisting of H, halo, C1-C3 alkyl, S(O)m3 and —OR16;
• R15 is C1-C3 alkyl or aryl;
• R16 is C1-C3 alkyl;
• R17 is independently selected from the group consisting of hydrogen, —OR4′,
• —SR5′, C1-C3 alkyl, C2-C3 alkenyl, halo, —CN, S(O)m2′, —COR4b, and —OC(O)—R15′;
• R4b and R4b′ are each independently selected from hydrogen and C1-C3 alkyl;
• R15′ is C1-C3 alkyl or aryl;
• m2′ is 0 to 2;
• R4′ is hydrogen, C1-C3 alkyl;
• R5′ is hydrogen, C1-C3 alkyl;
• m2 is 0 to 2;
• X is selected from the group consisting of C, O, S, N, carbonyl, and a bond;
• n′ is 0 to 2;
• m′ is 0 to 2;
• m3 is 0 to 2;
• n is 0 to 3;
• or
• a pharmaceutically acceptable salt or solvate thereof.

A compound of Formula IV 27

• R21 and R22 are selected from H and O;
• R20 is selected from amine protecting groups;
• R1′ selected from the group consisting of —OR4, —SR5, C1-C3 alkyl, C2-C3 alkenyl, halo, —CN, S(O)m2, —COR4b′, and —OC(O)—R15;
• m2 is 0 to 2;
• R4 and R4b′ are each independently selected from hydrogen and C1-C3 alkyl;
• R5 is selected from hydrogen and C1-C3 alkyl;
• R15 is C1-C3 alkyl or aryl;
• or
• a pharmaceutically acceptable salt or solvate thereof.

A compound of the Formula V:

• 28
• E1+ is selected from the group consisting of C1-C10 alkyl, substituted C1-C10 alkyl, C2-C10 alkenyl, substituted C2-C10 alkenyl, C3-C8 cycloalkyl, substituted C3-C8 cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, and aryl electrophile;
• R11 is selected from the group consisting of hydrogen and C1-C3 alkyl;
• R12 is independently selected from the group consisting of hydrogen, C1-C10 alkyl, and aryl;
• R13 is independently selected from the group consisting of hydrogen, C1-C10 alkyl, and aryl;
• or
• R12 and R13 together with the nitrogen to which they are attached form a group of the formula II:
• 29
• II′ wherein the II′ group is a group of Formula II which is unsaturated;
• or
• R11 and R12 together with the nitrogen and carbon to which they are bound can join to form a three to six membered ring;
• R14 is selected from the group consisting of H, halo, C1-C3 alkyl, S(O)m3 and —OR16;
• R16 is C1-C3 alkyl;
• R17 is independently selected from the group consisting of hydrogen, —OR4′,
• —SR5′, C1-C3 alkyl, C2-C3 alkenyl, halo, —CN, S(O)m2′, —COR4b, and —OC(O)—R15′;
• R4b and R4b′ are each independently selected from hydrogen and C1-C3 alkyl;
• R15′ is C1-C3 alkyl or aryl;
• m2′ is 0 to 2;
• R4′ is hydrogen, C1-C3 alkyl;
• R5′ is hydrogen, C1-C3 alkyl;
• m2 is 0 to 2;
• X is selected from the group consisting of C, O, S, N, carbonyl, and a bond;
• n′ is 0 to 2;
• m′ is 0 to 2;
• m3 is 0 to 2;
• n is 0 to 3;
• or
• a pharmaceutically acceptable salt or solvate thereof.